European Biopharma Co. Symphogen Raises $131M
Symphogen, a Copenhagen-based biopharmaceutical company focused on treatments for cancer and infectious and autoimmune diseases, has raised 100 million euros ($131 million) in new financing. Novo A/S led the round, which included participation from existing shareholder Essex Woodlands Health Ventures. Novo and Essex Woodlands are contributing 70% of the financing, which is slated to occur over three tranches. The Danish pension fund PKA also joined as a new investor.
6 January 2011•6 mins read
